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Apolipoprotein E (APOE) genotype determines Alzheimer’s disease (AD) susceptibility, with the APOE e4 allele being an established risk factor for lateonset AD. The ApoE lipidation status has been reported to impact amyloidbeta (Ab) peptide metabolism. The details of how lipidation affects ApoE
behavior remain to be elucidated. In this study, we prepared lipid-free and
lipid-bound ApoE particles, mimicking the high-density lipoprotein particles
found in vivo, for all three isoforms (ApoE2, ApoE3, and ApoE4) and biophysically characterized them. We find that lipid-free ApoE in solution has
the tendency to aggregate in vitro in an isoform-dependent manner under
near-physiological conditions and that aggregation is impeded by lipidation of
ApoE.
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Lipids require specialized carriers that transport them
through the body, known as apolipoproteins.
Apolipoproteins facilitate lipid solubilization and serve
as ligands for lipoprotein receptors that mediate cellular lipid uptake and play a role in cell signaling [1].
Apolipoprotein E (ApoE) is one of the most studied
members of this protein family, as the APOE genotype
has been linked to several neurological disorders, with
a strong association with Alzheimer’s disease (AD)

[2,3]. ApoE is produced in abundance in the human
brain by astrocytes, in less extent by macrophages and
stressed neurons, and is the principal lipid transporter
in the cerebrospinal fluid [4].
ApoE exists as three isoforms: ApoE2, ApoE3, and
ApoE4 [5]. The APOE e4 allele is the most important
genetic risk factor for development of late-onset AD.
People carrying one or two copies of the APOE e4
allele have respectively about 3- and 12-fold more risk
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of acquiring AD than non-APOE e4 carriers [6]. In
contrast, the APOE e2 allele is protective [7]. ApoE
was initially found to colocalize with plaques containing the amyloid-beta (Ab) peptide in AD brains [8].
Substantial evidence exists that ApoE contributes to
AD pathogenesis by modulating Ab aggregation and
clearance, and by regulating brain lipid metabolism
and synaptic functioning through ApoE receptors such
as those of the low-density lipoprotein (LDL) receptor
family [9–12]. Proposed Ab-independent roles for
ApoE4 in AD include generation of neurotoxic ApoE
fragments, impairment of mitochondrial function, and
disruption of the cytoskeleton through stimulation of
tau phosphorylation [13].
Although the ApoE isoforms only differ by their
amino acid compositions at positions 112 and 158 [14],
these changes have profound effects on the structure
and lipoprotein-binding preferences of the isoforms
[15,16]. ApoE consists of two structural domains linked
by a flexible hinge region. Although the N- and C-terminal domains interact in ApoE4, this interaction does not
occur to the same extent in ApoE2 and ApoE3 [17]. The
N-terminal receptor-binding domain is an extended
four-helix bundle and is responsible for binding to the
LDL receptor. The C-terminal domain of ApoE comprises several amphipathic a-helices and contains the
lipid-binding region that is capable of binding different
types of lipids (e.g., cholesterol, phospholipids, fatty
acids) and lipoproteins, including LDLs, very low-density lipoproteins (VLDLs), and high-density lipoproteins (HDLs). ApoE in the human brain is mainly
synthesized by and secreted from astrocytes to generate
ApoE-containing HDL-like particles. It has been suggested that astrocyte-secreted HDL particles are discoidal in shape, but the conformation adopted by ApoE
in the lipid complexes remains controversial [16].
The mechanistic link between ApoE and AD has
been the subject of numerous studies and debates, but
it has become clear that the lipidation status of ApoE
plays an important role. For the most part, biologically active ApoE is associated with lipids [18] and the
ApoE lipidation status has been reported to impact
Ab metabolism, that is, Ab aggregation and deposition
[19–22], and clearance [23–26]. For example, enhanced
expression of lipidated ApoE in AD mouse models,
through activation of liver X receptors or through
overexpression of the ATP-binding cassette A that is
responsible for ApoE lipidation, stimulates Ab clearance [23,27]. Therefore, modulators of ApoE secretion
and lipidation are being explored as potential drugs
for AD therapy [22,28,29].
Studying ApoE behavior in its lipid-free and lipidbound state is thus of great importance to enhance
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our understanding of its functioning in the context of
AD pathology. In this study, we therefore produced
all three ApoE isoforms in their lipidated and nonlipidated forms, and systematically characterized and
compared them by a range of biophysical techniques.
The lipidation procedure was carefully selected to
mimic in vivo discoidal HDL-like ApoE particles with
a physiological lipid composition consisting of phospholipid and unesterified cholesterol [30–32]. Our
results confirm the previously reported tendency of
lipid-free ApoE to self-assemble in solution [33–36]
and provide experimental evidence that lipidation protects ApoE from aggregation.

Materials and methods
Preparation of HDL-like ApoE particles
Preparation of reconstituted ApoE
Lyophilized recombinant human ApoE (Leinco Technologies, Inc., St Louis, MO, USA) was resuspended to a concentration of 1 mgmL 1 in Dulbecco’s phosphate-buffered
saline (DPBS, Thermo Fisher Scientific, Landsmeer, The
Netherlands) pH 7.4 containing 0.05 mM dithiothreitol.

Liposome preparation
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC,
Avanti Lipids) and unesterified cholesterol (Avanti Polar
Lipids) were mixed in a glass vial at a molar ratio of 90 : 5
and dried under a constant nitrogen gas stream. This ratio
was selected to mimic the physiological lipid composition
of HDL-like ApoE particles [30,31]. Lipids were resuspended in PBS at a concentration of 5 lg lipidslL 1 PBS.
The solution was mixed thoroughly in a vortex mixer and
intermittently for 5–10 min (with 1–2 min intervals) to generate liposomes. Complete hydration of liposomes was
accomplished by incubating the solution at room temperature for 30 min and occasional vortex mixing.

ApoE lipidation
Lipids can be added directly to ApoE but lipidated particles will be more homogeneous when using the sodium cholate dialysis method [32,37,38]. Therefore, sodium cholate
(50 mgmL 1, Sigma-Aldrich, St. Louis, MO, USA) was
slowly titrated into the liposome solution (2–3 volumes of
sodium cholate for 1 volume of lipids). The solution turbidity cleared after 5 min of gentle vortex mixing (1 min interval) and the preparation was kept at room temperature for
30–60 min. Reconstituted ApoE was then added to the
liposome preparation (ApoE : POPC : cholesterol, molar
ratio of 1 : 90 : 5) and mixed gently for 5–10 min (1–2 min

FEBS Letters 593 (2019) 1144–1153 ª 2019 The Authors. FEBS Letters published by John Wiley & Sons Ltd
on behalf of Federation of European Biochemical Societies.

1145

E. Hubin et al.

Lipidation-mediated prevention of apoE aggregation

interval). The solution was kept at room temperature for
1 h and dialyzed (10 kDa cutoff membrane) against PBS
for 4 h at room temperature (to promote removal of detergents), followed by 60–72 h at 4 °C. After dialysis, samples
were analyzed by gel filtration chromatography (Superdex
200 10/300 GL) and nondenaturing (native) polyacrylamide
gel electrophoresis (PAGE). ApoE concentrations were
determined by absorbance measurements at 280 nm using
an extinction coefficient of 44 460 M 1cm 1 [39]. Samples
were diluted in PBS to 0.1 mgmL 1 prior to further analysis. All lipoprotein samples were prepared using the same
lipid–cholesterol suspension and the procedure was performed in parallel. Samples were stored at 4 °C.

TEM imaging of lipid-free and lipid-bound ApoE
A staining procedure was adapted to assess the formation
of HDL-like ApoE particles with TEM [40]. Briefly, carbon-coated Formvar 400-mesh copper grids (AgarScientific,
Stansted, UK) were glow discharged prior to sample application. Lipidated ApoE (2 lL of a 0.1 mgmL 1 sample)
was spotted and incubated on the grids for 2 min at room
temperature. The grids were subsequently blotted, washed
(3 9 2 s, in ultrapure water), and stained with 1% (w/v)
uranyl acetate (2 9 2 min). For imaging of lipid-free ApoE,
samples were spotted and incubated on grids for 30 s, blotted, washed (1 9 5 s), and stained with 1% uranyl acetate
(1 9 30 s). Samples were studied with a JEM-1400 microscope (JEOL Ltd., Tokyo, Japan) at 80 kV. Images are representative of at least three independently prepared samples.

Native PAGE
Lipoprotein particle formation was assessed by native
PAGE. Equal amounts of ApoE isoforms (3 lg) were
mixed with Novex Tris-Glycine Native Sample Buffer
(1 : 1) to obtain a final volume of 15 lL, and loaded on a
4–20% Tris-glycine gel (Invitrogen). The gel was run at
100 V for 16 h at 4 °C. Sample migration was assessed
using the NativeMarkTM Unstained protein standard (Life
Technologies).

FFF-MALS
For each fractionation, a volume of 10 lL ApoE
(0.1 mgmL 1) was injected in an Eclipse asymmetrical flow
field flow fractionation (FFF) system (Wyatt Technology,
Santa Barbara, CA, USA), and the flow rate out of the
channel was maintained at 1 mLmin 1. Fractionated samples were analyzed with multiangle light scattering (MALS)
using the DAWN HELEOS system (Wyatt Technology),
an ultraviolet (UV) detector, and an Optilab rEX refractive
index detector (Wyatt Technology) connected to the Eclipse
system. The MALS system was equipped with a laser
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operating at 658 nm and measurements were taken at
14.4°, 25.9°, 34.8°, 42.8°, 51.5°, 60.0°, 69.3°, 79.7°, 90.0°,
100.3°, 110.7°, 121.2°, 132.2°, 142.5°, 152.5°, and 163.3°,
with reference to the axis of the incident beam. ASTRA V
software (version 5.3.4.14) (Wyatt Technology, Santa Barbara, CA, USA) was used for data acquisition and correction for interdetector delay and band broadening.

DLS
Lipid-free and lipid-bound ApoE (0.1 mgmL 1 in PBS)
were analyzed using dynamic light scattering (DLS). DLS
experiments were conducted with a DynaPro DLS plate
reader (Wyatt Technology) at 25 °C and at a scattering
angle of 158°. Data were analyzed using Dynamics software (Wyatt Technology) and represent the averages of 15
acquisitions (10 s per acquisition).

CD
ApoE isoforms (0.1 mgmL 1 in PBS) in the absence and
presence of lipids were placed in a quartz cuvette with an
optical path of 0.1 cm. Far-UV circular dichroism (CD)
spectra were recorded in a Jasco J-715 spectropolarimeter
(Jasco, Tokyo, Japan) at 25 °C. The wavelength range was
set from 260 to 190 nm with 0.2-nm resolution, 8.0-s
response time, and 1.0-nm bandwidth. Data were collected
as averages of eight scans at a scanning speed of
50 nmmin 1. Spectra were corrected by subtracting the
buffer baseline. Measurements were performed as independent duplicates. Data are presented as the mean residue
ellipticity (MRE, in deg cm2dmol 1). Secondary structure
content was estimated using CDSSTR software and the normalized root mean square deviation (NRMSD) is displayed
as a measure of correspondence between the experimental
and calculated reference spectra [41,42].

Intrinsic tryptophan fluorescence
Emission fluorescence spectra of lipidated and nonlipidated
ApoE isoforms (0.1 mgmL 1 in PBS) were measured using
a LS 55 spectrometer (PerkinElmer, Waltham, MA, USA)
at 25 °C. The excitation wavelength was set to 280 nm
(5 nm bandwidth) and the emission intensity was scanned
from 300 to 450 nm (5 nm bandwidth) at a scan speed of
100 nmmin 1. Spectra were corrected for buffer and represent averages of eight scans. Measurements were performed
as independent duplicates.

Results
Astrocyte-secreted ApoE in the brain is predominantly
associated with cholesterol and phospholipid-rich
HDL-like complexes [30,31]. Therefore, HDL-like
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ApoE particles were prepared using 1-palmitoyl-2oleoyl-sn-glycero-3-phosphocholine (POPC) and unesterified cholesterol, in a 1 : 90 : 5 molar ratio
(ApoE : POPC : cholesterol), using the sodium cholate
dialysis method described previously [38]. The lipidation procedure was assessed by transmission electron
microscopy (TEM) and revealed discoidal lipidated
ApoE particles (Fig. 1).
The sodium cholate procedure resulted in a heterogeneous population of lipid-bound ApoE particles, as
shown by field flow fractionation multiangle light scattering (FFF-MALS) analysis that detected three fractions with different retention times (Fig. 2). FFF is a
high-resolution separation technique that consists of a
velocity gradient inside a channel that separates particles based on their size. Smaller particles will be more
rapidly transported through the channel than larger
ones and will elute first, as opposed to size-exclusion
chromatography. The heterogeneity detected for lipidated ApoE particles is consistent with previous studies reporting different sizes for ApoE-containing
lipoproteins secreted by astrocytes from transgenic
mice expressing human ApoE, and in cerebrospinal
fluid (CSF) of human subjects [31,43,44].
Next, ApoE isoforms in their lipid-free and lipidbound state were characterized using FFF-MALS,
native polyacrylamide gel electrophoresis (PAGE), and
dynamic light scattering (DLS). The first particles to
elute from the FFF channel were the HDL-like ApoE
particles, and not the lipid-free ApoE isoforms, as
detected by differential refractive index analysis
(Fig. 2A), MALS (Fig. 2B), and UV absorbance
(Fig. 2C). Although lipid-free ApoE was eluted around
15 min, lipidated ApoE particles displayed shorter
retention times, that is, between 12 and 14 min. This
result indicates that the size of lipidated ApoE, and
specifically the hydrodynamic radius, is smaller than
that of lipid-free ApoE. Accordingly, native PAGE
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revealed that lipid-bound ApoE migrated further in the
4–20% Tris-glycine gel than lipid-free ApoE (Fig. 3A).
Moreover, estimations of the hydrodynamic radii by
DLS confirmed that lipidated ApoE, regardless of the
ApoE isoform, was smaller than lipid-free ApoE
(Fig. 3B). Together, these results suggest that lipid-free
ApoE has the tendency to aggregate in solution at a
concentration of 0.1 mgmL 1, whereas lipidation is
capable of impeding this behavior. This tendency is isoform dependent, with the most pronounced aggregation
for ApoE4, followed by ApoE3 and ApoE2 (Fig. 3).
The aggregation of lipid-free ApoE4 was visualized
by TEM and revealed amorphous aggregates (Fig. 4).
To assess the effect of lipidation on secondary structure content of ApoE, circular dichroism (CD) measurements were performed. Lipid-free as well as lipid-bound
ApoE displayed a predominant a-helical structural signature, characterized by two minima around 208 and
222 nm (Fig. 5A). Lipid-free and lipidated ApoE displayed approximately 60% a-helicity (Fig. 5B), which
corresponds to values reported previously [45]. The
mean residue ellipticity was, however, slightly increased
in the lipidated ApoE state with a small gain of a-helicity and loss of b-sheet structure (Fig. 5B). However,
taken into account an approximate error of 5% in the
measurements, the overall effect of lipidation on the secondary structure of ApoE was minor.
In contrast, more pronounced differences could be
observed in terms of tertiary structure, when lipid-free
and lipid-bound ApoE were compared by their intrinsic Trp fluorescence. ApoE has seven Trp residues:
four are located in the N-terminal domain and three
are situated in the C-terminal lipid-binding domain.
ApoE particles displayed a marked blue shift in their
fluorescence maximum upon lipidation (Fig. 6). We
attribute this blue shift to tertiary structural alterations
in the vicinity of the Trp residues resulting in an
increased hydrophobic environment.

Fig. 1. Assessment of the formation of
HDL-like discoidal ApoE particles with
TEM. The majority of the discoidal ApoE
particles are visualized from their top/
bottom, but some can also be seen from a
lateral perspective (indicated by arrows).
The scale bars represent 200 nm. The
image is representative of at least three
independently prepared samples.
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Fig. 2. The heterogeneous composition of HDL-like ApoE particles. Lipid-free and HDL-like ApoE particles (0.1 mgmL 1 in PBS) were
separated by FFF and their composition was compared by their (A) differential refractive index, (B) intensity of differential light scattering,
and (C) UV absorbance at 215 nm. Obtained spectra are representative of two independently prepared ApoE isoform samples.

A

B

Fig. 3. Lipidation impedes aggregation of
ApoE. Migration patterns and size
distributions of lipid-free and HDL-like
ApoE particles (0.1 mgmL 1 in PBS) were
obtained by native PAGE and DLS,
respectively. (A) Lipidated ApoE migrates
further in a 4–20% Tris-glycine gel
compared to lipid-free ApoE (M:
NativeMarkTM Unstained protein
standard). (B) The hydrodynamic radius of
lipidated ApoE is smaller than that of lipidfree ApoE. Obtained data are
representative of two independently
prepared ApoE isoform samples.
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Fig. 4. Lipid-free ApoE4 self-assembles
into amorphous aggregates. (A) Lipid-free
ApoE aggregates displayed an amorphous
morphology, similar for all three isoforms,
as assessed by TEM. Lipid-free ApoE4
aggregates are depicted. (B) An enlarged
image of lipid-free ApoE4 aggregates. The
scale bars represent 200 nm. Images are
representative of at least three
independently prepared samples.
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Fig. 5. Effect of lipidation on the secondary structure of ApoE. The
secondary structure content of lipid-free and HDL-like ApoE
particles (0.1 mgmL 1 in PBS) was studied by CD. (A) CD reveals
a predominant a-helical structural signature for all samples
characterized by double minima around 208 and 222 nm. (B)
Secondary structure content of each sample was estimated using
CDSSTR software [41,42]. The goodness of fit of the experimental
CD data with the reference data is indicated by the NRMSD value.
Spectra are averages of two independently prepared duplicates.

Discussion
ApoE has been reported to self-assemble [33–36] and
the hypothesis has been raised that the amphipathic ahelical structure of ApoE is stabilized upon lipid

binding, which may protect it from amyloidogenic
folding pathways [36]. We provide experimental evidence that lipidation indeed impedes aggregation of
ApoE, by comparing lipid-free ApoE and HDL-like
discoidal ApoE particles of all three ApoE isoforms
using a biophysical approach.
Our results show that lipid-free ApoE has the tendency to self-assemble, with ApoE4 having the highest
aggregation propensity, followed by ApoE3 and
ApoE2 (Figs 2–4). This is in accordance with previous
observations that provide evidence that ApoE
oligomerizes through a monomer–dimer–tetramer association process [34], and can aggregate further from
tetramers to higher molecular weight aggregates
[33,35]. These aggregates displayed an a-helical structure, in accordance with our results (Fig. 5) [36].
Moreover, the ApoE aggregation rate was previously
shown to be isoform dependent (ApoE4 > ApoE3 >
ApoE2), which was attributed to differences in conformational stability of the ApoE N-terminal region, with
a decreased stability resulting in a higher aggregation
rate [36]. Not only ApoE but also other apolipoproteins including ApoA-I, ApoA-II, and ApoB100 display low conformational stability and have the
tendency to self-assemble [46].
Despite the importance of the stability of the N terminus, several studies have appointed the C terminus
as the main determinant of ApoE self-assembly
[35,47–50]. The C terminus of ApoE comprises amphipathic a-helices and exposes a large, hydrophobic surface [17]. As the lipid-binding region of ApoE is
situated in the C-terminal region of ApoE, it was
hypothesized that there might be a link between ApoE
self-assembly and its lipid-binding properties [51,52].
Accordingly, we provide experimental evidence that
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Fig. 6. Effect of lipidation on the tertiary structure of ApoE. (A) Intrinsic Trp fluorescence emission spectra (kex = 280 nm) corresponding to
lipid-free and HDL-like ApoE particles (0.1 mgmL 1 in PBS). (B) The maximum of the Trp fluorescence emission spectrum of lipidated ApoE
is blue shifted compared to that of lipid-free ApoE. Statistical significance of the results was established by P-values using unpaired twotailed t-tests, with *P < 0.05. Spectra are averages of two independently prepared duplicates.

lipidation impedes ApoE self-assembly into amorphous
aggregates, as ApoE bound to lipids is smaller than
when alone in solution, based on its hydrodynamic
radius and migration properties (Figs 2–4). Lipidation
has minor effects on the secondary structure of ApoE,
with the main contribution still arising from a-helices
(Fig. 5), but elicits tertiary structural alterations in the
vicinity of Trp residues (Fig. 6). This observation is
consistent with the general consensus that ApoE
undergoes a lipid binding-induced conformational
rearrangement [16]. It has been suggested that lipidation might stabilize the amphipathic a-helical structure
of ApoE and protect it against aggregation [36]. This
is not a property solely applicable to ApoE but also to
other apolipoproteins that contain a large proportion
of amphipathic a-helices and display low conformational stability in the absence of lipids [46]. It is conceivable that variations in lipid composition may
influence the observations made, as it has been shown
that distinct discoidal ApoE lipid complexes are
formed when varying POPC and cholesterol levels [53].
Further studies are required to establish the impact of
levels and type of surface and core lipids on aggregation of ApoE.
Although ApoE mostly occurs in its lipid-bound
form in plasma and CSF, there are lipid-poor reservoirs and conditions that are vulnerable to aggregation
(e.g., ApoE synthesized by macrophages and neurons
in stress conditions) [36]. Therefore, the higher propensity of lipid-free ApoE4 in solution to aggregate compared to other ApoE isoforms as shown by our data,
1150

and its ability to form aggregates that are toxic to neuronal cells [36], might underlie its association with
AD.
In conclusion, we report that lipid-free ApoE in solution has the tendency to aggregate in vitro in an isoformdependent manner (ApoE4 > ApoE3 > ApoE2) under
near-physiological conditions and that aggregation is
impeded by lipidation of ApoE. As ApoE4 aggregates
have been demonstrated to be toxic to neuronal cells,
these findings might explain the higher AD risk associated with ApoE4 in comparison with other ApoE
isoforms.
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